ZA902710B - Enzyme luminescence assay - Google Patents

Enzyme luminescence assay

Info

Publication number
ZA902710B
ZA902710B ZA902710A ZA902710A ZA902710B ZA 902710 B ZA902710 B ZA 902710B ZA 902710 A ZA902710 A ZA 902710A ZA 902710 A ZA902710 A ZA 902710A ZA 902710 B ZA902710 B ZA 902710B
Authority
ZA
South Africa
Prior art keywords
luminescence assay
enzyme luminescence
enzyme
assay
luminescence
Prior art date
Application number
ZA902710A
Inventor
Richard D Cummings
D Cummings Richard
Milton J Cormier
J Cormier Milton
Original Assignee
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found filed Critical Univ Georgia Res Found
Publication of ZA902710B publication Critical patent/ZA902710B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA902710A 1989-05-22 1990-04-09 Enzyme luminescence assay ZA902710B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35568989A 1989-05-22 1989-05-22

Publications (1)

Publication Number Publication Date
ZA902710B true ZA902710B (en) 1991-12-24

Family

ID=23398419

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA902710A ZA902710B (en) 1989-05-22 1990-04-09 Enzyme luminescence assay

Country Status (3)

Country Link
AU (1) AU5811290A (en)
WO (1) WO1990014074A1 (en)
ZA (1) ZA902710B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
WO1995001164A1 (en) * 1993-06-30 1995-01-12 Genentech, Inc. Method for preparing liposomes
CA2201631C (en) * 1994-10-03 2004-05-04 Michel G. Bergeron Liposome-formulations for treatment of viral diseases
GB9519654D0 (en) * 1995-09-27 1995-11-29 Nycomed Imaging As Stabilised phospholipid compositions
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6274313B1 (en) 1996-03-21 2001-08-14 Pioneer-Hybrid International, Inc. Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use
US6331617B1 (en) 1996-03-21 2001-12-18 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
AU3514197A (en) 1996-07-03 1998-01-21 Genetics Institute Inc. Protease fmh-1, an ice/ced-like protease
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
JP4999255B2 (en) 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド Oligonucleotide-containing pharmacological composition and use thereof
EP1470148B1 (en) 2002-02-01 2012-07-18 Life Technologies Corporation Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
RU2424792C2 (en) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Liposomes used for delivery of medications
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US9315862B2 (en) 2004-10-05 2016-04-19 California Institute Of Technology Aptamer regulated nucleic acids and uses thereof
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
EP2980220A1 (en) 2005-09-20 2016-02-03 BASF Plant Science GmbH Improved methods controlling gene expression
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US9029524B2 (en) 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
CN102016036B (en) 2008-02-11 2015-04-08 阿克赛医药公司 Modified RNAi polynucleotides and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2949752B1 (en) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
CN103108642B (en) 2010-03-24 2015-09-23 雷克西制药公司 RNA in skin and fibrotic conditions disturbs
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
WO2015085113A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102506169B1 (en) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
JP6983752B2 (en) 2015-07-06 2021-12-17 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. Nucleic acid molecule targeting superoxide dismutase 1 (SOD1)
BR122021024957B1 (en) 2015-10-16 2023-12-12 Ipsen Biopharm Ltd Processes for producing a storage-stabilized liposomal irinotecan composition
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CR20200251A (en) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039830A (en) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR20210099573A (en) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. Selection of improved tumor-reactive T-cells
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
SG11202109331QA (en) 2019-03-01 2021-09-29 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2023501445A (en) 2019-11-08 2023-01-18 フィオ ファーマシューティカルズ コーポレーション Chemically modified oligonucleotides targeting bromodomain-containing protein 4 (BRD4) for immunotherapy
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
WO2021138537A1 (en) 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
TW202208617A (en) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
CN118043459A (en) 2021-08-04 2024-05-14 菲奥医药公司 Chemically modified oligonucleotides
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564599A (en) * 1982-08-23 1986-01-14 The Liposome Company, Inc. Liposome composition for lupus assay
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
JPH03501253A (en) * 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Liposome-based nucleoside analogs for the treatment of AIDS

Also Published As

Publication number Publication date
WO1990014074A1 (en) 1990-11-29
AU5811290A (en) 1990-12-18

Similar Documents

Publication Publication Date Title
ZA902710B (en) Enzyme luminescence assay
GB8705650D0 (en) Assay technique
GB2196118B (en) Enhanced luminescent assay
GB8910958D0 (en) Assay
GB8913474D0 (en) Assay method
GB8701687D0 (en) Assay technique
AU630181B2 (en) Enzyme luminescence assay
EP0502103A4 (en) Direct fibrinogen assay
GB8919411D0 (en) Assay method
GB8718304D0 (en) Enzymatic assay
EP0437013A3 (en) Luminescent assays
GB8727479D0 (en) Riboflavin-linked assay
GB8800292D0 (en) Assay method
GB8801199D0 (en) Dual enzyme assay
GB8820375D0 (en) Assay
NZ229069A (en) Two stage luminescent or luminometric assay
GB8621495D0 (en) Assay
GB2237383B (en) Enhanced chemiluminescent assay
GB8922909D0 (en) Assay method
GB8918223D0 (en) Assay
GB8811400D0 (en) Assay using de-aminating enzymes
GB8922265D0 (en) Assay methods
GB8713418D0 (en) Assay
GB8714213D0 (en) Assay
GB8719631D0 (en) Assay